The apolipoprotein E ε4 allele and antidepressant efficacy in cognitively intact elderly depressed patients

Biological Psychiatry

Volumn 54, Issue 7, 2003, Pages 665-673

  Murphy Jr , Greer M ^a   Kremer, Charlotte ^b   Rodrigues, Heidi ^b   Schatzberg, Alan F ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Organon Pharmaceuticals   (United States)

Author keywords

Aging; Antidepressant; Apolipoprotein E; Major depression; Pharmacogenetics

Indexed keywords

APOLIPOPROTEIN E; MIRTAZAPINE; PAROXETINE; ANTIDEPRESSANT AGENT; DRUG DERIVATIVE; MIANSERIN;

AGED; AGING; ALLELE; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; ETHNIC DIFFERENCE; FEMALE; GENOTYPE; HAMILTON SCALE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MOOD; MULTICENTER STUDY; PATIENT COMPLIANCE; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SEX DIFFERENCE; SIDE EFFECT; TREATMENT OUTCOME; BLOOD; COMPARATIVE STUDY; DEPRESSION; DRUG EFFECT; GENETICS; GERONTOPSYCHIATRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; TIME;

AGED; AGED, 80 AND OVER; ALLELES; ANTIDEPRESSIVE AGENTS; APOLIPOPROTEINS E; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COGNITION; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; GERIATRIC PSYCHIATRY; HUMANS; MALE; MIANSERIN; NEUROPSYCHOLOGICAL TESTS; PAROXETINE; PSYCHIATRIC STATUS RATING SCALES; TIME FACTORS; TREATMENT OUTCOME;

EID: 0142040221     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(03)00174-4     Document Type: Article

References (49)

1. Alberts M.J., Graffagnino C., McClenny C., DeLong D., Strittmatter W., Saunders A.M., Roses A.D. ApoE genotype and survival from intracerebral haemorrhage. Lancet. 346:1995;575.
2. Benkert O., Szegedi A., Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry. 61:2000;656-663.
3. Bondi M.W., Salmon D.P., Monsch A.U., Galasko D., Butters N., Klauber M.R., et al. Episodic memory changes are associated with the APOE-epsilon 4 allele in nondemented older adults. Neurology. 45:1995;2203-2206.
4. Brown E.S., Rush A.J., McEwen B.S. Hippocampal remodeling and damage by corticosteroids Implications for mood disorders . Neuropsychopharmacology. 21:1999;474-484.
5. Caselli R.J., Osborne D., Reiman E.M., Hentz J.G., Barbieri C.J., Saunders A.M., et al. Preclinical cognitive decline in late middle-aged asymptomatic apolipoprotein E-E4/4 homozygotes A replication study . J Neurol Sci. 189:2001;93-98.
6. Chapman S., Michaelson D.M. Specific neurochemical derangements of brain projecting neurons in apolipoprotein E-deficient mice. J Neurochem. 70:1998;708-714.
7. Chapman S., Sabo T., Roses A.D., Michaelson D.M. Reversal of presynaptic deficits of apolipoprotein E-deficient mice in human apolipoprotein E transgenic mice. Neuroscience. 97:2000;419-424.
8. Class C.A., Unverzagt F.W., Gao S., Sahota A., Hall K.S., Hendrie H.C. The association between Apo E genotype and depressive symptoms in elderly African-American subjects. Am J Geriatr Psychiatry. 5:1997;339-343.
9. Crum R.M., Anthony J.C., Bassett S.S., Folstein M.F. Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA. 269:1993;2386-2391.
10. de Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry. 57:1996;19-25.
11. de Boer T.H., Nefkens F., van Helvoirt A., van Delft A.M. Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan. J Pharmacol Exp Ther. 277:1996;852-860.
12. Dechant K.L., Clissold S.P. Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs. 41:1991;225-253.
13. Farrer L.A., Cupples L.A., Haines J.L., Hyman B., Kukull W.A., Mayeux R., et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 278:1997;1349-1356.
14. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 12:1975;189-198.
15. Forsell Y., Corder E.H., Basun H., Lannfelt L., Viitanen M., Winblad B. Depression and dementia in relation to apolipoprotein E polymorphism in a population sample age 75+. Biol Psychiatry. 42:1997;898-903.
16. Friedman G., Froom P., Sazbon L., Grinblatt I., Shochina M., Tsenter J., et al. Apolipoprotein E-epsilon4 genotype predicts a poor outcome in survivors of traumatic brain injury. Neurology. 52:1999;244-248.
17. Gordon I., Ben-Eliyahu S., Rosenne E., Sehayek E., Michaelson D.M. Derangement in stress response of apolipoprotein E-deficient mice. Neurosci Lett. 206:1996;212-214.
18. Guy W (1976): ECDEU Assessment Manual for Psychopharmacology, revised ed. DHEW Publication No. (ADM) 76-338. Rockville, MD: Department of Health, Education, and Welfare.
19. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 6:1967;278-296.
20. Han S.H., Chung S.Y. Marked hippocampal neuronal damage without motor deficits after mild concussive-like brain injury in apolipoprotein E-deficient mice. Ann N Y Acad Sci. 903:2000;357-365.
21. Horsburgh K., Kelly S., McCulloch J., Higgins G.A., Roses A.D., Nicoll J.A. Increased neuronal damage in apolipoprotein E-deficient mice following global ischaemia. Neuroreport. 10:1999;837-841.
22. Horsburgh K., McCulloch J., Nilsen M., Roses A.D., Nicoll J.A. Increased neuronal damage and apoE immunoreactivity in human apolipoprotein E, E4 isoform-specific, transgenic mice after global cerebral ischaemia. Eur J Neurosci. 12:2000;4309-4317.
23. Jordan B.D., Relkin N.R., Ravdin L.D., Jacobs A.R., Bennett A., Gandy S. Apolipoprotein E epsilon4 associated with chronic traumatic brain injury in boxing. JAMA. 278:1997;136-140.
24. Laskowitz D.T., Sheng H., Bart R.D., Joyner K.A., Roses A.D., Warner D.S. Apolipoprotein E-deficient mice have increased susceptibility to focal cerebral ischemia. J Cereb Blood Flow Metab. 17:1997;753-758.
25. Leinonen E., Skarstein J., Behnke K., Agren H., Helsdingen J.T. Efficacy and tolerability of mirtazapine versus citalopram A double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group . Int Clin Psychopharmacol. 14:1999;329-337.
26. Leonard B.E. Evidence for a biochemical lesion in depression. J Clin Psychiatry. 61:2000;12-17.
27. Louis E.J., Dempster E.R. An exact test for Hardy-Weinberg and multiple alleles. Biometrics. 43:1987;805-811.
28. Mauricio M., O'Hara R., Yesavage J.A., Friedman L., Kraemer H.C., Van De Water M., Murphy G.M. Jr. A longitudinal study of apolipoprotein-E genotype and depressive symptoms in community-dwelling older adults. Am J Geriatr Psychiatry. 8:2000;196-200.
29. Mulsant B.H., Pollock B.G., Nebes R.D., Miller M.D., Little J.T., Stack J., et al. A double-blind randomized comparison of nortriptyline and paroxetine in the treatment of late-life depression 6-week outcome . J Clin Psychiatry. 60:1999;16-20.
30. Murphy G.M. Jr, Taylor J., Kraemer H.C., Yesavage J., Tinklenberg J.R. No association between apolipoprotein E epsilon 4 allele and rate of decline in Alzheimer's disease. Am J Psychiatry. 154:1997;603-608.
31. Newman M.F., Croughwell N.D., Blumenthal J.A., Lowry E., White W.D., Spillane W., et al. Predictors of cognitive decline after cardiac operation. Ann Thorac Surg. 59:1995;1326-1330.
32. Nicoll J.A., Roberts G.W., Graham D.I. Apolipoprotein E epsilon 4 allele is associated with deposition of amyloid beta-protein following head injury. Nat Med. 1:1995;135-137.
33. O'Hara R., Yesavage J.A., Kraemer H.C., Mauricio M., Friedman L.F., Murphy G.M. Jr. The APOE epsilon4 allele is associated with decline on delayed recall performance in community-dwelling older adults. J Am Geriatr Soc. 46:1998;1493-1498.
34. Owens M.J., Knight D.L., Nemeroff C.B. Paroxetine binding to the rat norepinephrine transporter in vivo. Biol Psychiatry. 47:2000;842-845.
35. Peskind E.R., Wilkinson C.W., Petrie E.C., Schellenberg G.D., Raskind M.A. Increased CSF cortisol in AD is a function of APOE genotype. Neurology. 56:2001;1094-1098.
36. Puolivali J., Pradier L., Riekkinen P. Jr. Impaired recovery of noradrenaline levels in apolipoprotein E-deficient mice after N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine lesion. Neuroscience. 95:2000;353-358.
37. Roses A.D. Pharmacogenetics and the practice of medicine. Nature. 405:2000;857-865.
38. Schatzberg A.F., Kremer C., Rodrigues H.E., Murphy G.M. Jr. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry. 10:2002;541-550.
39. Schmand B., Hooijer C., Jonker C., Lindeboom J., Havekes L.M. Apolipoprotein E phenotype is not related to late-life depression in a population-based sample. Soc Psychiatry Psychiatr Epidemiol. 33:1998;21-26.
40. Schule C., Baghai T., Goy J., Bidlingmaier M., Strasburger C., Laakmann G. The influence of mirtazapine on anterior pituitary hormone secretion in healthy male subjects. Psychopharmacology (Berl). 163:2002;95-101.
41. Sheng H., Laskowitz D.T., Bennett E., Schmechel D.E., Bart R.D., Saunders A.M., et al. Apolipoprotein E isoform-specific differences in outcome from focal ischemia in transgenic mice. J Cereb Blood Flow Metab. 18:1998;361-366.
42. Sheng H., Laskowitz D.T., Mackensen G.B., Kudo M., Pearlstein R.D., Warner D.S. Apolipoprotein E deficiency worsens outcome from global cerebral ischemia in the mouse. Stroke. 30:1999;1118-1124.
43. Small G.W., Chen S.T., Komo S., Ercoli L., Bookheimer S., Miller K., et al. Memory self-appraisal in middle-aged and older adults with the apolipoprotein E-4 allele. Am J Psychiatry. 156:1999;1035-1038.
44. Sorbi S., Nacmias B., Piacentini S., Repice A., Latorraca S., Forleo P., Amaducci L. ApoE as a prognostic factor for post-traumatic coma. Nat Med. 1:1995;852.
45. Stahl S.M. Basic psychopharmacology of antidepressants, part 1 Antidepressants have seven distinct mechanisms of action . J Clin Psychiatry. 59:1998;5-14.
46. Stahl S.M., Nierenberg A.A., Gorman J.M. Evidence of early onset of antidepressant effect in randomized controlled trials. J Clin Psychiatry. 62:2001;17-23.
47. Walters G., Reynolds C.F. 3rd, Mulsant B.H., Pollock B.G. Continuation and maintenance pharmacotherapy in geriatric depression An open-trial comparison of paroxetine and nortriptyline in patients older than 70 years . J Clin Psychiatry. 60:1999;21-25. ; discussion: 37-40.
48. Wheatley D.P., van Moffaert M., Timmerman L., Kremer C.M. Mirtazapine Efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group . J Clin Psychiatry. 59:1998;306-312.
49. Yesavage J.A., Brink T.L., Rose T.L., Lum O., Huang V., Adey M., Leirer V.O. Development and validation of a geriatric depression screening scale A preliminary report . J Psychiat Res. 17:1983;37-49.